No description
-
2013 (v1)PublicationUploaded on: April 14, 2023
-
2012 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2013 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2016 (v1)Publication
HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. In these types of cancer, accurate assessment of HER2 status is mandatory, for selecting patients who may benefit from targeted therapies with anti-HER2 drugs such as Trastuzumab. This manuscript focuses on HER2 in gastric carcinogenesis, on...
Uploaded on: March 27, 2023 -
2013 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2013 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2013 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2015 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2017 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2012 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2012 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2015 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2014 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2014 (v1)Publication
No description
Uploaded on: April 14, 2023